Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia

被引：7

作者：

Nakaya, Aya ^{[1
]}

Fujita, Shinya ^{[1
]}

Satake, Atsushi ^{[1
]}

Nakanishi, Takahisa ^{[1
]}

Azuma, Yoshiko ^{[1
]}

Tsubokura, Yukie ^{[1
]}

Hotta, Masaaki ^{[1
]}

Yoshimura, Hideaki ^{[1
]}

Ishii, Kazuyoshi ^{[1
]}

Ito, Tomoki ^{[1
]}

Nomura, Shosaku ^{[1
]}

机构：

[1] Kansai Med Univ, Dept Internal Med 1, 2-5-1 Shinmachi, Hirakata, Osaka, Japan

来源：

HEMATOLOGY REPORTS | 2018年 / 10卷 / 03期

关键词：

Chronic myeloid leukemia; Dasatinib; large granular lymphocyte; pleural effusion; late-onset; adverse event;

D O I：

10.4081/hr.2018.7474

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dasatinib is currently approved for clinical use as a first-line treatment agent for newly diagnosed chronic myeloid leukemia (CML). However, only a few clinical trials have been performed to evaluate dasatinib-induced PE following first-line therapy. We investigated the incidence and clinical features of dasatinib-induced PE following first-line therapy in Japanese CML patients of real world clinical practice settings. Among 22 patients, the median age of PE-positive patients was higher than that of PE-negative patients. Major molecular response was achieved in 75% of PE-positive patients and 50% of PE-negative patients. Most patients developed PE more than 1 year after treatment. Appearance of PE is associated with better clinical response during dasatinib treatment, however it is developed at any time. Elderly and high-risk patients tend to develop PE. The clinical features of dasatinib-induced PE following first-line therapy might be late onset and might not immediately follow the increasing of large granular lymphocyte.

引用

页码：65 / 68

页数：4

共 16 条

[1] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[2] Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis [J].

Cortes, Jorge ;

Rousselot, Philippe ;

Kim, Dong-Wook ;

Ritchie, Ellen ;

Hamerschlak, Nelson ;

Coutre, Steven ;

Hochhaus, Andreas ;

Guilhot, Francois ;

Saglio, Giuseppe ;

Apperley, Jane ;

Ottmann, Oliver ;

Shah, Neil ;

Erben, Philipp ;

Branford, Susan ;

Agarwal, Prasheen ;

Gollerkeri, Ashwin ;

Baccarani, Michele .

BLOOD, 2007, 109 (08) :3207-3213

[3] Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management [J].

Cortes, Jorge E. ;

Jimenez, Carlos A. ;

Mauro, Michael J. ;

Geyer, Alex ;

Pinilla-Ibarz, Javier ;

Smith, B. Douglas .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (02) :78-82

[4] Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial [J].

Cortes, Jorge E. ;

Saglio, Giuseppe ;

Kantarjian, Hagop M. ;

Baccarani, Michele ;

Mayer, Jiri ;

Boque, Concepcion ;

Shah, Neil P. ;

Chuah, Charles ;

Casanova, Luis ;

Bradley-Garelik, Brigid ;

Manos, George ;

Hochhaus, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (20) :2333-U54

[5] Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion [J].

Eskazan, Ahmet Emre ;

Eyice, Deniz ;

Kurt, Enes Ali ;

Elverdi, Tugrul ;

Yalniz, Fevzi Firat ;

Salihoglu, Ayse ;

Ar, Muhlis Cem ;

Aydin, Seniz Ongoren ;

Baslar, Zafer ;

Ferhanoglu, Burhan ;

Aydin, Yildiz ;

Tuzuner, Nukhet ;

Ozbek, Ugur ;

Soysal, Teoman .

LEUKEMIA RESEARCH, 2014, 38 (07) :781-787

[6] Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up [J].

Fujisawa, Shin ;

Nakamae, Hirohisa ;

Ogura, Michinori ;

Ishizawa, Ken-ichi ;

Taniwaki, Masafumi ;

Utsunomiya, Atae ;

Matsue, Kosei ;

Takamatsu, Yasushi ;

Usuki, Kensuke ;

Tanimoto, Mitsune ;

Ishida, Yoji ;

Akiyama, Hideki ;

Onishi, Shintaro .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 99 (02) :141-153

[7] Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase [J].

Guilhot, Francois ;

Apperley, Jane ;

Kim, Dong-Wook ;

Bullorsky, Eduardo O. ;

Baccarani, Michele ;

Roboz, Gail J. ;

Amadori, Sergio ;

de Souza, Carmino A. ;

Lipton, Jeffrey H. ;

Hochhaus, Andreas ;

Heim, Dominik ;

Larson, Richard A. ;

Branford, Susan ;

Muller, Martin C. ;

Agarwal, Prasheen ;

Gollerkeri, Ashwin ;

Talpaz, Moshe .

BLOOD, 2007, 109 (10) :4143-4150

[8] Association of pleural effusion with an early molecular response. in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study [J].

Hagihara, Maki ;

Iriyama, Noriyoshi ;

Yoshida, Chikashi ;

Wakita, Hisashi ;

Chiba, Shigeru ;

Okamoto, Shinichiro ;

Kawakami, Kimihiro ;

Takezako, Naoki ;

Kumagai, Takashi ;

Inokuchi, Koiti ;

Ohyashiki, Kazuma ;

Taguchi, Jun ;

Yano, Shingo ;

Igarashi, Tadahiko ;

Kouzai, Yasuji ;

Morita, Satoshi ;

Sakamoto, Junichi ;

Sakamaki, Hisashi .

ONCOLOGY REPORTS, 2016, 36 (05) :2976-2982

[9] Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib [J].

Hochhaus, A. ;

Baccarani, M. ;

Deininger, M. ;

Apperley, J. F. ;

Lipton, J. H. ;

Goldberg, S. L. ;

Corm, S. ;

Shah, N. P. ;

Cervantes, F. ;

Silver, R. T. ;

Niederwieser, D. ;

Stone, R. M. ;

Dombret, H. ;

Larson, R. A. ;

Roy, L. ;

Hughes, T. ;

Mueller, M. C. ;

Ezzeddine, R. ;

Countouriotis, A. M. ;

Kantarjian, H. M. .

LEUKEMIA, 2008, 22 (06) :1200-1206

[10] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia [J].

Kantarjian, Hagop ;

Shah, Neil P. ;

Hochhaus, Andreas ;

Cortes, Jorge ;

Shah, Sandip ;

Ayala, Manuel ;

Moiraghi, Beatriz ;

Shen, Zhixiang ;

Mayer, Jiri ;

Pasquini, Ricardo ;

Nakamae, Hirohisa ;

Huguet, Francoise ;

Boque, Concepcion ;

Chuah, Charles ;

Bleickardt, Eric ;

Bradley-Garelik, M. Brigid ;

Zhu, Chao ;

Szatrowski, Ted ;

Shapiro, David ;

Baccarani, Michele .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) :2260-2270

← 1 2 →